Journal Articles
2020

COVID-19 and Thrombotic or Thromboembolic Disease:
Implications for Prevention, Antithrombotic Therapy, and FollowUp: JACC State-of-the-Art Review
B. Bikdeli
M. V. Madhavan
D. Jimenez
T. Chuich
I. Dreyfus

See next page for additional authors

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Internal Medicine Commons

Recommended Citation
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian CD, Ageno W,
Spyropoulos AC, Lip GY, . COVID-19 and Thrombotic or Thromboembolic Disease: Implications for
Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. . 2020 Jan 01;
75(23):Article 6157 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/6157. Free
full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic
Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara
Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.

Authors
B. Bikdeli, M. V. Madhavan, D. Jimenez, T. Chuich, I. Dreyfus, E. Driggin, C. D. Nigoghossian, W. Ageno, A. C.
Spyropoulos, G. Y. Lip, and +10 additional authors

This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/6157

Since January 2020 Elsevier has created a COVID-19 resource centre with
free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the
company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related
research that is available on the COVID-19 resource centre - including this
research content - immediately available in PubMed Central and other
publicly funded repositories, such as the WHO COVID database with rights
for unrestricted research re-use and analyses in any form or by any means
with acknowledgement of the original source. These permissions are
granted for free by Elsevier for as long as the COVID-19 resource centre
remains active.

Journal Pre-proof
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention,
Antithrombotic Therapy, and Follow-up
Behnood Bikdeli, MD, MS, Mahesh V. Madhavan, MD, David Jimenez, MD, PhD,
Taylor Chuich, PharmD, Isaac Dreyfus, MD, Elissa Driggin, MD, Caroline Der
Nigoghossian, PharmD, Walter Ageno, MD, Mohammad Madjid, MD, MS, Yutao Guo,
MD, PhD, Liang V. Tang, MD, Yu Hu, MD, Jay Giri, MD, MPH, Mary Cushman, MD,
MSc, Isabelle Quéré, MD, PhD, Evangelos P. Dimakakos, MD, C. Michael Gibson,
MD, Giuseppe Lippi, MD, Emmanuel J. Favaloro, PhD, Jawed Fareed, PhD, Joseph
A. Caprini, MD, MS, Alfonso J. Tafur, MD, MS, John R. Burton, BS, Dominic P.
Francese, MPH, Elizabeth Y. Wang, MD, Anna Falanga, MD, Claire McLintock, MD,
Beverley J. Hunt, MD, Alex C. Spyropoulos, MD, Geoffrey D. Barnes, MD, MSc, John
W. Eikelboom, MBBS, Ido Weinberg, MD, Sam Schulman, MD, PhD, Marc Carrier,
MD, MSc, Gregory Piazza, MD, MS, Joshua A. Beckman, MD, P. Gabriel Steg, MD,
Gregg W. Stone, MD, Stephan Rosenkranz, MD, Samuel Z. Goldhaber, MD, Sahil
A. Parikh, MD, Manuel Monreal, MD, PhD, Harlan M. Krumholz, MD, SM, Stavros V.
Konstantinides, MD, PhD, Jeffrey I. Weitz, MD, Gregory Y.H. Lip, MD
PII:

S0735-1097(20)35008-7

DOI:

https://doi.org/10.1016/j.jacc.2020.04.031

Reference:

JAC 27284

To appear in:

Journal of the American College of Cardiology

Received Date: 15 April 2020
Accepted Date: 15 April 2020

Please cite this article as: Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E,
Nigoghossian CD, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos
EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang
EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I,
Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ,
Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH, COVID-19 and Thrombotic
or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up,
Journal of the American College of Cardiology (2020), doi: https://doi.org/10.1016/j.jacc.2020.04.031.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2020 Published by Elsevier on behalf of the American College of Cardiology Foundation.

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention,
Antithrombotic Therapy, and Follow-up
Running Head: COVID-19 and Thrombotic Disease
Behnood Bikdeli, MD, MS1,2,3*, Mahesh V. Madhavan, MD1,3*, David Jimenez MD, PhD4,
Taylor Chuich, PharmD1, Isaac Dreyfus, MD1, Elissa Driggin, MD1, Caroline Der Nigoghossian,
PharmD1, Walter Ageno, MD5, Mohammad Madjid, MD, MS6, Yutao Guo, MD, PhD7, Liang V.
Tang, MD8, Yu Hu, MD8, Jay Giri, MD, MPH9,10,11, Mary Cushman, MD, MSc12, Isabelle
Quéré, MD, PhD13, Evangelos P. Dimakakos, MD14, C. Michael Gibson, MD15,16, Giuseppe
Lippi, MD17, Emmanuel J. Favaloro, PhD18,19, Jawed Fareed, PhD20, Joseph A. Caprini, MD,
MS21, Alfonso J. Tafur, MD, MS21,22, John R. Burton, BS1, Dominic P. Francese, MPH3,
Elizabeth Y. Wang, MD1, Anna Falanga, MD23, Claire McLintock, MD24, Beverley J. Hunt,
MD25, Alex C. Spyropoulos, MD26, Geoffrey D. Barnes, MD, MSc27,28, John W. Eikelboom,
MBBS29, Ido Weinberg, MD30, Sam Schulman, MD, PhD31,43,44, Marc Carrier, MD, MSc32,
Gregory Piazza, MD, MS15,33, Joshua A. Beckman, MD34, P. Gabriel Steg, MD35,36,37, Gregg W.
Stone, MD3,38, Stephan Rosenkranz, MD39, Samuel Z. Goldhaber, MD15, 33, Sahil A. Parikh,
MD1,3, Manuel Monreal, MD, PhD40, Harlan M. Krumholz, MD, SM2,41, Stavros V.
Konstantinides, MD, PhD42, Jeffrey I. Weitz, MD43,44, Gregory Y.H. Lip, MD45,46
Endorsed by the International Society on Thrombosis and Haemostasis (ISTH), the North
American Thrombosis Forum (NATF), the European Society of Vascular Medicine (ESVM),
and the International Union of Angiology (IUA). Supported by the ESC Working Group on the
Pulmonary Circulation and Right Ventricular Function (SR, SK).
From 1NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York,
New York; 2Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine,
New Haven, Connecticut; 3Clinical Trials Center, Cardiovascular Research Foundation, New
York, New York; 4Respiratory Department, Hospital Ramón y Cajal and Medicine Department,
Universidad de Alcalá (IRYCIS), CIBER de Enfermedades Respiratorias (CIBERES), Madrid,
Spain; 5Department of Medicine and Surgery, University of Insubria, Varese, Italy; 6McGovern
Medical School at The University of Texas Health Science Center at Houston, Houston, Texas;
7
Department of Cardiology, Chinese PLA General Hospital, Beijing, China; 8 Institute of
Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and
Technology, Wuhan, China; 9Cardiovascular Division, Hospital of the University of
Pennsylvania, Philadelphia; 10Penn Cardiovascular Outcomes, Quality, and Evaluative Research
Center, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia;
11
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania; 12The
University of Vermont Medical Center, Burlington, Vermont; 13Department of Vascular
Medicine, University of Montpellier, Montpellier CHU, InnoVTE F-CRIN network, Montpellier,
France; 14Oncology Unit GPP, Sotiria General Hospital Athens School of Medicine, Athens,
Greece; 15Harvard Medical School, Boston, Massachusetts; 16Beth Israel Deaconess Medical
Center, Boston, Massachusetts; 17Laboratory of Clinical Chemistry and Hematology, University
Hospital of Verona, Verona, Italy; 18Laboratory Haematology, Institute of Clinical Pathology and
Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW,
Australia; 19Sydney Centres for Thrombosis and Haemostasis, Westmead, NSW, Australia;

1

Loyola University Medical Center, Chicago, Illinois; 21Pritzker School of Medicine at the
University of Chicago, Chicago, Illinois; 22Division of Vascular Medicine, Department of
Medicine, NorthShore University HealthSystem, Skokie, Illinois;23University of Milan Bicocca,
Monza, Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni
XXIII, Bergamo, Italy, 24Auckland City Hospital, Auckland, New Zealand, 25St Thomas’
Hospital, London, United Kingdom, 26The Donald and Barbara Zucker School of Medicine at
Hofstra/Northwell, New York, New York 27Center for Bioethics and Social Science in
Medicine, 28Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan;
29
Population Health Research Institute, McMaster University and Hamilton Health Sciences,
Hamilton, Ontario, Canada; 30Massachusetts General Hospital, Boston, Massachusetts;
31
Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical
University, Moscow, Russia; 32The Ottawa Hospital Research Institute, Ottawa, Ontario,
Canada; 33Brigham and Women’s Hospital, Boston, Massachusetts; 34Vanderbilt University
School of Medicine, Nashville, Tennessee; 35FACT (French Alliance for Cardiovascular Trials),
Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, INSERM U1148, Paris, France;
36
Université Paris, Paris, France; 37Imperial College, Royal Brompton Hospital, London, United
Kingdom; 38The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of
Medicine at Mount Sinai, New York, New York; 39 Department of Cardiology, Heart Center at
the University of Cologne, and Cologne Cardiovascular Research Center (CCRC), University of
Cologne, Germany ; 40Department of Internal Medicine, Hospital Universitari Germans Trials I
Pujol, Universidad Católica de Murcia, Barcelona, Spain; 41Department of Health Policy and
Administration, Yale School of Public Health, New Haven, Connecticut; 42Center for
Thrombosis and Hemostasis, Johannes Gutenberg University of Mainz, Mainz, Germany;
43
McMaster University, Hamilton, Ontario, Canada; 44Thrombosis & Atherosclerosis Research
Institute, Hamilton, Ontario, Canada; 45Liverpool Centre for Cardiovascular Science, University
of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; 46Aalborg
University, Aalborg, Denmark
*Drs. Bikdeli and Madhavan contributed equally to this manuscript.
Disclosures
Dr. Bikdeli reports that he is a consulting expert, on behalf of the plaintiff, for litigation related
to a specific type of IVC filters.
Dr. Madhavan reports being supported by an institutional grant by the National Institutes of
Health/ National Heart, Lung, and Blood Institute to Columbia University Irving Medical Center
(T32 HL007854).
Dr. Jimenez has served as an advisor or consultant for Bayer HealthCare Pharmaceuticals,
Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Leo Pharma, Pfizer, ROVI and
Sanofi; served as a speaker or a member of a speakers’ bureau for Bayer HealthCare
Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Leo Pharma,
ROVI and Sanofi; received grants for clinical research from Daiichi Sankyo, Sanofi and ROVI.
Dr. Hu has nothing to disclose.
Dr. Chuich has nothing to disclose.
Dr. Dreyfus has nothing to disclose.
Dr. Driggin has nothing to disclose.
Dr. Der Nigoghossian has nothing to disclose.

2

Dr. Tang has nothing to disclose.
Dr. Ageno has received honoraria from Boehringer Ingelheim, Bayer Pharmaceuticals, BMSPfizer, Daiichi-Sankyo, Aspen, Sanofi, Portola, Janssen. Research support from Bayer
Pharmaceuticals.
Dr. Dimakakos receives consulting fees from Sanofi and Leo.
Dr. Lippi has nothing to disclose.
Dr. Favaloro has nothing to disclose.
Dr. Fareed has nothing to disclose.
Dr. Caprini: Steering committee – Janssen R&D; bleeding advisory board – Pfizer; honorarium –
Sanofi; consultant – Recovery Force; advisory board – Bristol-Myers Squibb, Alexion
Pharmaceuticals.
Dr. Cushman has nothing to disclose.
Dr. Barnes reports consulting for Pfizer/Bristol-Myers Squib, Janssen, Portola, and AMAG
Pharmaceuticals. Grant funding from Pfizer/Bristol-Myers Squibb and Blue Cross Blue Shield of
Michigan.
Dr. Cushman has nothing to disclose.
Dr. Giri is on the Advisory Boards for Astra Zeneca, Philips Medical, and Inari Medical,
receives Research Grants to Institution from Recor Medical and St Jude Medical, and receives
Personal Fees for Trial Adjudication from New England Research Institute.
Dr Quéré has received honoraria from Bayer Pharmaceuticals, BMS-Pfizer, Leo Pharma and
Aspen.
Dr. Falanga reports being a speaker at corporate symposia for Bayer, Pfizer, and Sanofi.
Dr Spyropoulos reports receiving consulting fees from Boehringer Ingelheim, BMS, Janssen,
Bayer, Portola, and the ATLAS Group, and research funding from Boehringer Ingelheim, and
Janssen.
Dr. Carrier reports Research funding from BMS, LEO Pharma and Pfizer and consultancy
honoraria from BMS, Bayer, Pfizer, LEO Pharma, Servier and Sanofi.
Dr McLintock has nothing to disclose.
Dr. Hunt reports she takes no monies in any form from pharmaceutical companies producing
thrombotic drugs. She is chair of the steering group of World Thrombosis Day and Medical
Director of Thrombosis UK; two non-for-profit organisations from which she takes no fees.
Dr. Weinberg reports consulting fees for Magneto thrombectomy solutions.
Dr. Piazza has received significant research grant support from BTG International, Bristol Myers
Squibb, Daiichi-Sankyo, Bayer, Portola, and Janssen and modest consulting fees from Pfizer and
Thrombolex.
Dr. Schulman reports research grants from Octapharma and Boehringer-Ingelheim and honoraria
from Alnylam, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo and Sanofi.
Dr. Beckman is on the Advisory Boards for Amgen, Astra Zeneca, Glaxo Smith Kline, and
Janssen, on the DSMB for Bayer, and Novartis, receives consulting fees from JanOne, and
personal fees for Trial Adjudication from Sanofi.
Dr. Rosenkranz: reports remunerations for consultancy and/or lectures from Abbott, Acceleron,
Actelion, AstraZeneca, Bayer, BMS, Janssen, MSD, Novartis, Pfizer, United Therapeutics.
Research grants to institution from Actelion, AstraZeneca, Bayer, Novartis; Deutsche
Forschungsgemeinschaft (DFG), Else-Bundesministerium für Bildung und Forschung (BMBF),
Kröner-Fresenius-Stiftung (EKFS).

3

Dr. Steg reports receiving research grants from Amarin, Bayer, Sanofi, and Servier, and is in the
Steering Committee, DSMB or CEC for clinical trials for: Amarin, AstraZeneca, Bayer,
Boehringer Ingelheim, Bristol-Myers Squibb, Idorsia, Novartis, Pfizer, Sanofi, Servier, and
receives speaker or consultant fees from: Amarin, AstraZeneca, Bayer, Boehringer Ingelheim,
Bristol-Myers Squibb, Idorsia, Novartis, Pfizer, Sanofi, and Servier.
Dr. Stone has received speaker or other honoraria from Cook, Terumo, QOOL Therapeutics and
Orchestra Biomed; has served as a consultant to Valfix, TherOx, Vascular Dynamics, Robocath,
HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA
Pharmaceuticals, Vectorious, Reva, Matrizyme; and has equity/options from Ancora, Qool
Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra
Biomed, Aria, Cardiac Success, MedFocus family of funds, Valfix.
Dr. Parikh reports institutional grants/research support from Abbott Vascular, Shockwave
Medical, TriReme Medical, Surmodics, and Silk Road Medical; consulting fees from Terumo
and Abiomed; and Advisory Board participation for Abbott, Boston Scientific, CSI, Janssen,
Medtronic and Philips.
Dr. Monreal reports that he served as an advisor or consultant for Sanofi, Leo Pharma and
Daiichi Sankyo. Also, he received a nonrestricted educational grant by Sanofi and Bayer to
sponsor the RIETE registry.
Dr. Krumholz works under contract with the Centers for Medicare & Medicaid Services to
support quality measurement programs; was a recipient of a research grant, through Yale, from
Medtronic and the U.S. Food and Drug Administration to develop methods for post-market
surveillance of medical devices; was a recipient of a research grant from Johnson & Johnson,
through Yale University, to support clinical trial data sharing; was a recipient of a research
agreement, through Yale University, from the Shenzhen Center for Health Information for work
to advance intelligent disease prevention and health promotion; collaborates with the National
Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law
Firm for work related to the Sanofi clopidogrel litigation, from the Martin Baughman Law Firm
for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law
Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for
UnitedHealth; was a member of the IBM Watson Health Life Sciences Board; is a member of the
Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician
Advisory Board for Aetna; and is the co-founder of HugoHealth, a personal health information
platform, and co-founder of Refactor Health, an enterprise healthcare AI-augmented data
management company.
Dr. Konstantinides reports research grants from Bayer AG, Boehringer Ingelheim, Actelion Janssen; educational grants from Biocompatibles Group UK - Boston Scientific, Daiichi Sankyo;
lecture fees from Bayer AG, Pfizer-Bristol-Myers Squibb, MSD, all outside the submitted work.
Dr. Weitz serves as a consultant and received honoraria from Bayer, Janssen, JnJ, BMS, Pfizer,
Boehringer Ingelheim, Novartis, Daiichi-Sankyo, Merck, Servier, Anthos, Ionis, and PhaseBio.
Dr. Lip reports that he is a Consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer
Ingelheim, Novartis, Verseon and Daiichi-Sankyo and a speaker for Bayer, BMS/Pfizer,
Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally.
Corresponding Authors:
Behnood Bikdeli, MD, MS
New York-Presbyterian Hospital/ Columbia University Irving Medical Center

4

622 West 168th St, PH 3-347, New York, NY 10032
Phone/ Fax: 212-305-6354
Email: bb2813@cumc.columbia.edu, Behnood.bikdeli@yale.edu
Twitter handle: @bbikdeli
Mahesh Vasantha Madhavan, MD
New York-Presbyterian Hospital/ Columbia University Irving Medical Center
622 West 168th St, PH 3-347, New York, NY 10032
Phone/ Fax: 212-305-6354
Email: mvm2122@cumc.columbia.edu
Twitter handle: @MVMadhavanMD
Acknowledgments
The authors would like to thank Kathryn Mikkelsen, MBA, from the North American
Thrombosis Forum, and Adriana Visonà, MD, from the European Society of Vascular Medicine
for their comments related to this initiative. The authors would like to credit Julie Der
Nigoghossian for assistance with graphic
design.

5

ABSTRACT
Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may predispose patients to thrombotic
disease, both in the venous and arterial circulations, due to excessive inflammation, platelet
activation, endothelial dysfunction, and stasis. In addition, many patients receiving
antithrombotic therapy for thrombotic disease may develop COVID-19, which can have
implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover,
during a time with much focus on COVID-19, it is critical to consider how to optimize the
available technology to care for patients without COVID-19 who have thrombotic disease.
Herein, we review the current understanding of the pathogenesis, epidemiology, management
and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of
those with preexisting thrombotic disease who develop COVID-19, or those who need
prevention or care for their thrombotic disease during the COVID-19 pandemic.
KEYWORDS: Coronavirus disease 2019, SARS-CoV-2, thrombosis, antithrombotic therapy,
anticoagulant, antiplatelet
ABBREVIATIONS
ACS = acute coronary syndromes
COVID-19 = coronavirus disease 2019
DAPT = dual antiplatelet therapy
DIC = disseminated intravascular coagulation
DOAC = direct oral anticoagulant
DVT = deep vein thrombosis
ECMO = extracorporeal membrane oxygenation
LMWH = low-molecular-weight heparin
PE = pulmonary embolism
PERTs = pulmonary embolism response teams
SARS-CoV2 = severe acute respiratory syndrome coronavirus 2
STEMI = ST-segment elevation myocardial infarction
UFH = unfractionated heparin
VEGF = vascular endothelial growth factor
VKA = vitamin-K antagonist
VTE = venous thromboembolism
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Introduction
The coronavirus disease of 2019 (COVID-19) is a viral illness caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV2), now deemed a pandemic by the World
Health Organization (1-3). COVID-19 has a number of important cardiovascular implications (46). Patients with prior cardiovascular disease are at higher risk for adverse events from COVID19. Individuals without a history of cardiovascular disease are at risk for incident cardiovascular
complications (5).
There are several ways in which the COVID-19 pandemic may affect the prevention and
management of thrombotic and thromboembolic disease (hereafter collectively referred to as
thrombotic disease for brevity). First, the direct effects of COVID-19 or the indirect effects of
infection, such as through severe illness and hypoxia, may predispose patients to thrombotic
events. Preliminary reports suggest that hemostatic abnormalities, including disseminated
intravascular coagulation (DIC), occur in patients affected by COVID-19 (7,8). Additionally, the
severe inflammatory response, critical illness, and underlying traditional risk factors may all
predispose to thrombotic events, similar to prior virulent zoonotic coronavirus outbreaks (Table
1) (9,10). Second, investigational therapies for treating COVID-19 may have adverse drug-drug
interactions with antiplatelet agents and anticoagulants. Third, the pandemic, because of resource
allocations or social distancing recommendations, may adversely affect the care of patients
without COVID-19 but who present with thrombotic events. For example, (mis)perception that
antithrombotic agents confer increased risk for contracting COVID-19, may lead to untoward
interruption of anticoagulation by some patients.
The current manuscript, authored by an international collaborative of clinicians and
investigators, summarizes the pathogenesis, epidemiology, treatment, and available outcome data
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related to thrombotic disease in patients with COVID-19, as well as management of thrombotic
events in patients without COVID-19 during this pandemic. Although the focus is on the
prevention and management of venous thromboembolism (VTE) and antithrombotic therapy for
acute coronary syndromes (ACS), many of the recommendations are relevant to other conditions
requiring antithrombotic therapy. We provide clinical guidance, when feasible, and also identify
areas that require urgent attention for future research.
Methodological Considerations
Every effort was made to provide a comprehensive assessment of the published evidence
(MEDLINE with PubMed interface, date of last search: April 12, 2020). To accommodate the
rapidly-evolving nature of information and concern for the delay between completion of studies
and their publication, we also reviewed manuscripts on two pre-print servers
(https://www.medrxiv.org/ and https://www.ssrn.com/index.cfm/en/coronavirus/, date of last
search April 12, 2020). We acknowledge that the manuscripts from the latter two sources are not
peer-reviewed.
There is international variability in preventive measures and testing strategies by local
authorities, diagnostic tests availability, access to care and treatment strategies, as well as
variability in outcome reporting for COVID-19. These issues influence the reported diagnosed
cases, casualties, and in turn case-fatality rates. Moreover, to date, we lack large prospective
cohorts. The existing evidence, including data on thrombotic complications, is derived primarily
from small and retrospective analyses (Figure 1).
The current document represents an effort to provide general guidance for patient-care
related to thrombosis and antithrombotic therapy. Given the limitations of the evidence base, the
steering committee (BB, MVM, JIW, SK, SZG, AT, MM, HMK, GYHL) chose several
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questions that seemed more challenging but relevant to patient care (11). These questions were
sent to the entire group of authors twice. The Delphi method was implemented to provide
consensus-based guidance. The questions included considerations for prophylactic or therapeutic
anticoagulant regimens among various subgroups of patients with COVID-19, and
antithrombotic therapy in the setting of suspected or confirmed DIC.
Pathogenesis and Transmission
SARS-CoV2 is a single-strand RNA coronavirus, which enters human cells mainly by
binding the angiotensin converting enzyme 2 (ACE2) (12), which is highly expressed in lung
alveolar cells, cardiac myocytes, the vascular endothelium, and other cells (1,13). SARS-CoV2 is
transmitted primarily after viral particles are inhaled and enter the respiratory tract (1). In
addition, the virus can survive for 24-72 hours on surfaces, depending on the type of surface,
which enables fomite transmission (14).
Initial symptoms of COVID-19 overlap with other viral syndromes, and include fever,
fatigue, headache, cough, shortness of breath, diarrhea, headaches, and myalgias (15-17). As
with other virulent zoonotic coronavirus infections such as severe acute respiratory syndrome
(SARS) and Middle Eastern respiratory syndrome (MERS-CoV), COVID-19 has the potential to
result in severe illness including systemic inflammatory response syndrome, acute respiratory
disease syndrome (ARDS), multi-organ involvement, and shock (18). Although older age and
comorbidities such as cardiovascular disease confer a higher risk for severe disease, young and
otherwise healthy patients are also at risk for complications (19).
Common laboratory abnormalities found in patients with COVID-19 include
lymphopenia (15) and elevation in lactate dehydrogenase and inflammatory markers such as, C-

9

reactive protein, D-dimer, ferritin and interleukin-6 (IL-6) (20). IL-6 levels may correlate with
disease severity, and a procoagulant profile (21).
COVID-19 and Hemostasis Parameters
The most consistent hemostatic abnormalities with COVID-19 include mild
thrombocytopenia (22) and increased D-dimer levels (23), which are associated with a higher
risk of requiring mechanical ventilation, intensive care unit [ICU] admission, or death. Data
related to other tests are less certain and often contradictory (24,25). Disease severity is variably
associated with prolongation of the prothrombin time (PT) and international normalized ratio
(INR) (1,20,26), and thrombin time (TT) (27), and variably by a trend toward shortened activated
partial thromboplastin time (aPTT) (1,16,19,28). Recently, Tang et al. (7) assessed 183 patients
with COVID-19, 21 of whom (11.5%) died. Among the notable differences between patients
who died and those who survived were increased levels of D-dimer and fibrin degradation
products ([FDPs], ~3.5- and ~1.9-fold increase, respectively) and PT prolongation (by 14%,
P<0.001). Further, 71% of COVID-19 patients who died fulfilled the International Society on
Thrombosis and Haemostasis (ISTH) criteria (29) for DIC, compared with only 0.6% among
survivors. Collectively, these hemostatic changes indicate some forms of coagulopathy that may
predispose to thrombotic events (Central Illustration), although the cause is uncertain.
Nevertheless, it is yet unknown whether these hemostatic changes are a specific effect of
SARS-CoV-2 or are a consequence of cytokine storm that precipitates the onset of systemic
inflammatory response syndrome (SIRS), as observed in other viral disease (30-33). Another
consideration which has not yet been investigated is that the hemostatic changes seen with
COVID-19 infection are related to liver dysfunction (34). A recent study reported 3 cases with
severe COVID-19 and cerebral infarction, one associated with bilateral limb ischemia, in the
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setting of elevated antiphospholipid antibodies. Whether antiphospholipid antibodies play a
major role in pathophysiology of thrombosis associated with COVID-19 requires further
investigation (35).
COVID-19, markers of myocardial injury, and thrombotic disease. Elevated troponin
levels are associated with poor outcomes in several studies of COVID-19 (36). However, the
differential diagnosis for elevated troponin in COVID-19 is broad (37) and includes non-specific
myocardial injury, impaired renal function (leading to troponin accumulation), myocarditis,
pulmonary embolism (PE), and Type I and II myocardial infarction (MI) (38,39). Similarly,
elevation of natriuretic peptides is non-specific (38), and consideration for thrombotic events
(e.g., PE) should only be raised in the appropriate clinical context.
COVID-19 Investigational Therapies and Considerations for Thrombotic Disease
Several investigational agents are being tested in the management of COVID-19,
especially for patients who develop severe disease. Some of these drugs have clinically important
interactions with antiplatelet or anticoagulant agents (Tables 4 and 5).
Further, a few of these investigational agents have been associated with excess risk (or, in
other cases, reduced risk) for thrombotic events, or for thrombocytopenia in prior studies of nonCOVID-19 populations. For example, bevacizumab, a monoclonal antibody that binds to
vascular endothelial growth factor (VEGF), and is under investigational use for COVID-19, is
associated with increased risk for adverse cardiovascular events, including MI, cerebrovascular
accidents, and VTE (40,41). Alternatively, fingolimod, an immunomodulating agent being tried
for COVID-19, may reduce reperfusion injury and improve outcomes in patients suffering from
acute ischemic stroke (42). Hydroxychorloquine, recently receiving Emergency Use
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Authorization from the U.S. Food and Drug Administration for treatment of COVID-19, may
potentially exert antithrombotic properties, especially against anti-phospholipid antibodies (43).
COVID-19 investigational therapies and antiplatelet agents.
Scientists are studying a number of agents for COVID-19 treatment that may have
interactions with oral antiplatelet agents. Table 3 presents potential drug interactions between
investigational drugs for COVID-19 and commonly administered oral antiplatelet agents.
Lopinavir/ritonavir is a protease inhibitor and inhibits CYP3A4 metabolism. Although the active
metabolite for clopidogrel is mostly formed by CYP2C19, inhibition of CYP3A4 may also lead
to reduction in effective dosage of clopidogrel. In contrast, inhibition of CYP3A4 may increase
effects of ticagrelor. Therefore, the concomitant use of these agents along with
lopinavir/ritonavir should be cautioned. Although limited clinical data exist, use of P2Y12 platelet
function testing to guide the use of clopidogrel or ticagrelor in this setting might be considered.
An alternative, in the absence of contraindications, is to use prasugrel, which is not prone to
these interactions (44-47). Remdesivir, a nucleotide-analog inhibitor of RNA-dependent RNA
polymerase, reportedly an inducer of CYP3A4; however, dose adjustments for oral antiplatelet
agents are currently not recommended. Of note, there are no major drug-drug interactions
between investigational COVID-19 therapies and parenteral antiplatelet agents such as cangrelor
and glycoprotein IIb/IIIa inhibitors.
COVID-19 investigational therapies and anticoagulants.
Table 4 summarizes interactions between investigational drugs for COVID-19 and
commonly administered oral anticoagulants. Lopinavir/ritonavir has the potential to also affect
choice and dosage of a number of anticoagulants. For example, vitamin K antagonists, apixaban,
and betrixaban may all require dose adjustment, while edoxaban and rivaroxaban should not be
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co-administered with lopinavir/ritonavir. Tocilizumab, an IL-6 inhibitor, increases expression of
CYP3A4; however, no anticoagulant dose adjustments are currently recommended with
concomitant use of tocilizumab at this time. There are no major drug-drug interactions between
investigational COVID-19 therapies and parenteral anticoagulants. Although the focus of the
current manuscript is primarily related to VTE and ACS, the guidance provided for
antithrombotic considerations is broadly relevant across other clinical indications.
COVID-19 and VTE
Risk stratification and in-hospital prophylaxis.
Hospitalized patients with acute medical illness, including infections such as pneumonia,
are at increased risk of VTE (48,49). Prophylactic anticoagulation reduces the risk of VTE in
acutely ill hospitalized medical patients (50-52), and appropriate use of VTE prophylaxis is
covered in clinical practice guidelines (49,53,54). Multiple risk stratification tools are available
for VTE risk assessment in this setting (e.g. the Caprini, IMPROVE, and Padua models) (55-60).
The choice of specific risk assessment model may vary across health system. However,
similar to other acutely ill medical patients, VTE risk stratification for hospitalized patients with
COVID-19 should be undertaken. A recent study from China, using the Padua model, reported
that 40% of hospitalized patients with COVID-19 were at high risk of VTE. The study did not
provide data about the use of VTE prophylaxis, or the incident VTE events (61). Hospitalized
patients with COVID-19 who have respiratory failure or co-morbidities (e.g., active cancer, or
heart failure) (62), patients who are bedridden, and those requiring intensive care should receive
pharmacological VTE prophylaxis, unless there are contraindications. The choice of agents and
dosing should be based on available guideline recommendations (53,54,63). The World Health
Organization interim guidance statement recommends prophylactic daily low-molecular weight
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heparins (LMWHs), or twice daily subcutaneous unfractionated heparin (UFH) (64). If
pharmacological prophylaxis is contraindicated, mechanical VTE prophylaxis (intermittent
pneumatic compression) should be considered in immobilized patients (64,65). Missed doses of
pharmacologic VTE prophylaxis are common and are likely associated with worse outcomes
(66). Therefore, every effort should be made to ensure that patients receive all scheduled doses
of pharmacologic VTE prophylaxis. In this regard, once daily dosing regimen of LMWHs may
be advantageous over UFH to reduce personal protective equipment (PPE) use and exposure of
healthcare workers.
Consideration for risk of VTE in pregnant patients with COVID-19 deserves further
attention. The risk of VTE is increased during pregnancy and the postpartum period (67,68).
Although limited data are available, pregnant women admitted to hospital with COVID-19
infection are likely to be at an increased risk of VTE. It is reasonable to assess the risk of VTE
and to consider pharmacological thromboprophylaxis, especially if they have other VTE risk
factors. Weight-adjusted prophylactic dosing of anticoagulation is an interesting topic that
requires additional investigation (69).
Extended (post-discharge) VTE prophylaxis.
After hospital discharge from acute medical illness, extended prophylaxis with LMWH
(70) or direct oral anticoagulants (DOACs) (71-74) can reduce the risk of VTE, at the cost of
increase in bleeding events, including major bleeding (75,76). While no data specific to COVID19 exist, it is reasonable to employ individualized risk stratification for thrombotic and
hemorrhagic risk, followed by consideration of extended prophylaxis (for up to 45 days) for
patients with elevated risk of VTE (e.g., reduced mobility, co-morbidities such as active cancer,
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and [according to some authors in the writing group], elevated D-dimer >2 times the upper
normal limit) who have low risk of bleeding (74,77,78).
The role of thromboprophylaxis for quarantined patients with mild COVID-19 but
significant co-morbidities, or for patients without COVID-19 who are less active because of
quarantine is uncertain. These patients should be advised to stay active at home. In the absence
of high-quality data, pharmacological prophylaxis should be reserved for those at highest risk
patients, including those with limited mobility and history of prior VTE or active malignancy.
Diagnosis of VTE in patients with COVID-19.
As described above, elevated D-dimer levels, is a common finding in patients with
COVID-19 (23), and does not currently warrant routine investigation for acute VTE in absence
of clinical manifestations or other supporting information. However, the index of suspicion for
VTE should be high in the case typical DVT symptoms, hypoxemia disproportionate to known
respiratory pathologies, or acute unexplained right ventricular dysfunction.
A diagnostic challenge arises among patients with COVID-19, as imaging studies used to
diagnose DVT or PE may not be pursued given risk of transmitting infection to other patients or
healthcare workers and potentially due to patient instability. Moreover, imaging studies may be
challenging in the setting of patients with severe ARDS who require prone positioning.
Investigation for PE is not feasible due to critical illness and prone position. Lower extremity
ultrasound is also limited due to patient positioning. Deterioration of right ventricular function in
this setting may be a critical finding, justifying the need for ways to diagnose and treat PE.
However, it may be argued that the prognosis of patients with ARDS requiring prone position is
so grave that investigation for underlying VTE may not alter the course. A potential option may
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be to consider echocardiography to assess for signs of potentially worsening right ventricular
dysfunction and in rare circumstances, clot in transit (79).
Role for empiric therapeutic anticoagulation without a diagnosis of VTE.
In view of the hemostatic derangements discussed above and observations from prior
viral illnesses (80), some clinicians use intermediate-dose or full dose (therapeutic) parenteral
anticoagulation (rather than prophylactic dosing) for routine care of patients with COVID-19
(81), hypothesizing that it may confer benefit to prevent microvascular thrombosis. However, the
existing data are very limited, primarily based on a subgroup analysis (N=97) from a single
retrospective study with limited control for potential confounders (82). A single center study
from China suggested that D-dimer levels >1,500ng/mL has a sensitivity of 85.0% and
specificity of 88.5% for detecting VTE events. However, the study was limited by small sample
size and lack of validation. At this moment, while practitioners use a variety of prophylactic,
intermediate, or therapeutic doses of anticoagulants in patients, the optimal dosing in patients
with severe COVID-19 remains unknown and warrants further prospective investigation. The
majority of panel members consider prophylactic anticoagulation, although a minority consider
intermediate-dose or therapeutic dose to be reasonable.
Incident venous thromboembolism.
Few published studies have commented on incident VTE in patients with COVID-19. In
a retrospective study from China, among 81 patients with severe COVID-19 admitted to ICU, 20
(25%) developed incident VTE. Of note, none of the patients had received VTE prophylaxis
(85). In an preprint study of 25 patients with COVID-19 from Wuhan, who were suspected of
having PE and underwent computed tomography angiography (CTA), 10 (40%) had evidence of
acute PE on imaging (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548771); however,
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the study did not provide information related to use of VTE prophylaxis or the reason for
performing CTA. In a study of 184 patients with severe COVID-19 from 3 academic medical
centers in the Netherlands, the authors reported that 31% (95%CI 20-41) of patients developed
incident VTE. All patients received pharmacological prophylaxis, although under-dosing was
observed in 2 of the 3 participating centers (81). These findings require validation in additional
studies.
It is possible but unknown that VTE remains underdiagnosed in patients with severe
COVID-19. This is important, as ARDS in patients with COVID-19 is, itself, a potential etiology
for hypoxic pulmonary vasoconstriction, pulmonary hypertension and right ventricular failure.
Further insult from PE may be unrecoverable.
Medical therapy for VTE.
Therapeutic anticoagulation is the mainstay of VTE treatment (49,86,87). Selection of an
agent requires consideration of comorbidities such as renal or hepatic dysfunction,
thrombocytopenia and gastrointestinal tract function, and the agent will likely change across the
hospital course to the time of discharge. In many ill inpatients with VTE, parenteral
anticoagulation (e.g. UFH) is preferred as it may be temporarily withheld and has no known
drug-drug interactions with investigational COVID-19 therapies. Concerns with UFH, however,
include the time to achieve therapeutic aPTT, and increased healthcare worker exposure for
frequent blood draws. Therefore, LMWHs may be preferred in patients unlikely to need
procedures. The benefit of oral anticoagulation with DOACs include the lack of need for
monitoring, facilitation of discharge planning, and outpatient management. The potential risk
(especially in the setting or organ dysfunction) may include clinical deterioration and lack of
timely availability of effective reversal agents at some centers. For patients who are ready for
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discharge, DOACs or LMWH would be preferred to limit contact of patients with healthcare
services required for INR monitoring for VKAs.
COVID-19 and interventional therapies for VTE.
Pulmonary embolism response teams (PERTs) allow for multidisciplinary care for
patients intermediate and high-risk with VTE (49,88-90). During the COVID-19 pandemic,
similar to other consultative services, PERTs should transition from in-person inpatient
evaluation to e-consults using phone calls or telemedicine systems whenever feasible. It is
important to note that, there are minimal available data demonstrating lower mortality from
routine use of advanced VTE therapies (91,92). Therefore, the use of catheter-directed therapies
during the current outbreak should be limited to the most critical situations. Indiscriminate use of
inferior vena cava filters should be avoided (93). Recurrent PE despite optimal anticoagulation,
or clinically-significant VTE in the setting of absolute contraindications to anticoagulation would
be among the few scenarios in which placement of an inferior vena cava filter may be considered
(11). Even after IVC filter placement, anticoagulation should be resumed as soon as feasible, and
this is often done with gradually increasing doses and close observation for bleeding. With
regard to reperfusion strategies for acute PE, current guideline recommendations should be
followed. Intermediate-risk hemodynamically stable patients (intermediate-low risk, or
intermediate-high risk PE according to ESC classification, sub-massive PE according to prior
classifications) (49,87,91,94) should be managed initially with anticoagulation and close
monitoring. In case of further deterioration, rescue systemic fibrinolysis should be considered,
with catheter-directed options as an alternative. For patients with overt hemodynamic instability
(high-risk PE according to the ESC classification, massive PE according to prior classifications)
(49,87,91,94) systemic fibrinolysis is indicated, with catheter-based therapies reserved for
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scenarios that are not suitable for systemic fibrinolysis. If infection control settings are equal,
bedside initiation of extracorporeal membrane oxygenation (ECMO) is preferred in cases with
known COVID-19 positivity or uncertain status, rather than support strategies requiring the use
of a catheterization laboratory or an operating room (95). Figure 2 presents a potential algorithm
for treatments based on risk due to VTE and COVID-19 severity.
The vast majority of patients with symptomatic acute deep venous thrombosis (DVT),
should be managed with anticoagulation, with home treatment whenever possible. The few that
may require acute endovascular techniques (either local fibrinolysis or embolectomy) include
those with phlegmasia, or truly refractory symptoms (96).
COVID-19 and Acute Coronary Syndromes
COVID-19 and incident ACS.
Myocardial injury in COVID-19, as evidenced by elevated cardiac troponin levels or
electrocardiographic and echocardiographic abnormalities, is associated with severe disease.7
Furthermore, higher troponin levels are associated with severe COVID-19 (5,97). However, not
all such events are due to thrombotic ACS. While anecdotal cases of patients with COVID-19
presenting with ACS due to plaque-rupture have been described (type I MI), currently no such
cases have been published. Such cases have been also previously described with influenza or
other viral illnesses, and have been attributed to a combination of SIRS as well as localized
vascular/plaque inflammation (10,98,99).
COVID-19 and antithrombotic therapy for ACS.
In presentations consistent with ACS due to plaque rupture (i.e. Type I MI) (39), dual
antiplatelet therapy (DAPT) and full dose anticoagulation per American College of Cardiology
(ACC)/American Heart Association (AHA) and the European Society of Cardiology (ESC)
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guidelines should be administered unless there are contraindications (100-103). In patients with
perceived elevated bleeding risk, regimens with less potent antiplatelet agents, such as with
clopidogrel, should be considered given that hemorrhagic complications are not uncommon.
Special attention should be also given to drug-drug interactions between antiplatelet agents or
anticoagulants and COVID-19 investigational therapies. Parenteral antithrombotic agents, in
general, do not have known major interactions with the COVID-19 investigational therapies
(Tables 4, 5).
COVID-19 and interventional therapies for ACS.
The American College of Cardiology (ACC) and Society for Cardiovascular
Angiography and Interventions (SCAI) recently provided guidance regarding catheterization
laboratory procedures in the current climate (84,104). The recommendations note that it is
reasonable to continue optimal medical therapy and defer non-urgent cardiac procedures, in
order to preserve PPE, hospital resources including inpatient and ICU beds, and minimize
exposure for patients and healthcare workers, alike.
Prior to intervention, efforts should be made to distinguish non-specific myocardial
injury, myocarditis, and true plaque rupture presentations (104). A low threshold to use
transthoracic echocardiography to identify wall motion abnormalities should be considered prior
to catheterization laboratory activation. Even in case of STEMI, in which primary percutaneous
coronary intervention (PCI) reduces mortality and reinfarction, risk of COVID-19 transmission
from patients to healthcare workers, or vice versa (asymptomatic vectors) must be considered. In
light of this, individual centers in China and elsewhere have developed adjusted ACS protocols,
which call for consideration of fibrinolytic therapy in selected patients with STEMI (105).
Centers in which timely percutaneous coronary intervention is less feasible may be more likely
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to adopt such a strategy. However, given that presentations of COVID-19 can mimic ACS (e.g.
in the setting of myocarditis), fibrinolytic therapy must be used with caution.
Critical Illness with SARS-CoV-2 and Management of Antithrombotic Agents
The risk of VTE, which is increased in critically ill patients, is likely even higher in those
with SARS-CoV-2 and critical illness. Aside from hemostatic derangements, immobility, an
systemic inflammatory state, mechanical ventilation and central venous catheters contribute to
VTE risk within the ICU (106-108), Nutritional deficiencies and liver dysfunction may also
interfere with the production of coagulation factors (109). Alterations in pharmacokinetics in
critically ill patients may necessitate anticoagulation dose adjustment (110), due to factors
relating to absorption, metabolism, and renal (or hepatic) elimination of these drugs in the setting
of potential organ dysfunction.
Parenteral anticoagulation is recommended in most cases in which anticoagulant therapy
is needed for known thrombotic disease. UFH can be used in the setting of anticipated
procedures, or in patients with deteriorating renal function. If no urgent procedures are
anticipated, LMWHs are a reasonable alternative (111). In patients requiring ECMO,
anticoagulation is frequently required to maintain circuit patency, especially at lower flow
settings. Rates of complications are unknown in patients with SARS-CoV-2, but rates of
thrombosis and hemorrhage may be as high as 53% and 16%, respectively, in other populations
with respiratory failure (112). The limited outcome data that are available for ECMO in patients
with SARS-CoV-2 suggest poor outcomes, with 5 of 6 patients dying in one series and 3 out of 3
in another (113,114). There are currently insufficient data to recommend anticoagulation targets
for COVID-19 patients requiring ECMO (115).
Additional considerations.
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As previously mentioned, severe COVID-19 may predispose to DIC with such patients
experiencing particularly poor outcomes (7). Supportive care and addressing the underlying
hypoxia or co-infection are appropriate (29). There are insufficient data to recommend
transfusion thresholds that differ from those recommended for other critically ill patients. If
invasive procedures are planned, prophylactic transfusion of platelets, fresh frozen plasma,
fibrinogen, and prothrombin complex concentrate may be considered (29). Lastly, patients
requiring targeted temperature management may exhibit prolongations of both PT and aPTT
without evidence of bleeding diathesis (116). Therefore, correction of coagulopathy in
unselected patients without overt bleeding, is not currently recommended.
DIC and Considerations for Antithrombotic Therapy
Diagnosis and management.
DIC is common in many patients with critical illness (117), including those with COVID19 (7,118). It is uncertain whether COVID-19 has unique characteristics to cause direct
activation of coagulation. The diagnosis of DIC is best established using the ISTH DIC score
calculator (29). Regular laboratory monitoring of platelet count, PT, D-dimer, and fibrinogen in
patients with COVID-19 is important to diagnose worsening coagulopathy. The first step in
management of DIC is to identify and treat the underlying condition(s). Bacterial superinfections
should be treated aggressively.
In addition to preventing VTE, LMWH prophylaxis may decrease thrombin generation
and modify the course of DIC. Preliminary results, albeit with small number of events and
limited adjustment, may suggest a favorable response from LMWH prophylaxis (82,118). Longacting antiplatelet agents should be generally discontinued in most patients with DIC, unless
required (e.g. recent ACS or stent implantation). For patients with moderate or severe COVID-19
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and an indication for dual antiplatelet therapy (e.g. PCI within the past 3 months or recent MI)
and with suspected or confirmed DIC without overt bleeding, in the absence of evidence
decisions for antiplatelet therapy need to be individualized. In general, it is reasonable to
continue dual antiplatelet therapy if platelet count ≥50,000, reduce to single antiplatelet therapy
if 25,000≤platelet count<50,000, and discontinue if platelets <25,000. However, these guidelines
may be revised upward or downward depending on the individualized relative risk of stentrelated thrombotic complications vs. bleeding. Recovery from DIC is dependent on endogenous
fibrinolysis breaking down the disseminated thrombi.
Management of bleeding:
Clinically-overt bleeding is uncommon in the setting of COVID-19. However, when
bleeding occurs in COVID-19-associated DIC, blood products support should be considered as
per septic coagulopathy (119). In summary, the mainstay of blood products transfusion are as
follows: platelet concentrate to maintain platelet count >50 × 109/L in DIC patients with active
bleeding or >20 × 109/L in those with a high risk of bleeding or requiring invasive procedures.,
fresh frozen plasma (FFP) (15-25 mL/kg) in patients with active bleeding with either prolonged
PT and/or aPTT ratios (>1.5 times normal) or decreased fibrinogen (<1.5 g/L), fibrinogen
concentrate or cryoprecipitate to patients with persisting severe hypofibrinogenemia (<1.5 g/L),
and prothrombin complex concentrate (PCC) if FFP transfusion is not possible. With the existing
data, tranexamic acid should not be used routinely in COVID-19-associated DIC.
Management of Patients with Thromboembolic Disease without COVID-19
The main goal of management for patients with known or new-onset thrombotic disease
but without COVID-19 is to provide sufficient antithrombotic protection, while minimizing
physical contact between patients and healthcare workers and health systems. Outpatient
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management or early discharge for acute VTE should be instituted when possible (120-122), and
early discharge after medication stabilization for low-risk ACS or PCI for high-risk ACS should
be considered (100-102). Telemedicine should be the preferred method of follow-up, and inperson visits should be reserved only for scenarios that cannot be addressed by telemedicine, or
that may potentially warrant hospitalization.
In general, pharmacotherapy in patients with known thrombotic disease and without
COVID-19, should be followed similar to the period prior to the pandemic. Although a recent
document from the CDC indicated an increased risk of severe COVID-19 in patients receiving
“blood thinners” (123), there is no evidence that antiplatelet agents or anticoagulants, increase
the risk of contracting COVID-19, or of developing severe COVID-19. Sufficient education
should be provided to patients for self-monitoring of symptoms, and to avoid unnecessary
emergency department visits for nuisance bleeding.
For patients receiving VKAs, frequent INR monitoring may pose logistical challenges
due to lockdowns and may unnecessarily increase the risk of being exposed to SARS-CoV-2.
Therefore, thoughtful considerations should be given to potential alternatives, including using
extended INR testing intervals if prior INRs have been stable (124). Other alternatives include
home-based INR checks, if this can be set up promptly, drive-through INR testing, or switching
to a DOAC or LMWHs when clinically appropriate (Figure 3). A summary of key
recommendations is presented in Table 6.
Impact of COVID-19 on Healthcare Workers and Health Systems
Considerations for healthcare workers.
The CDC recommends contact and droplet personal PPE for healthcare workers in their
routine care of patients with COVID-19. If an aerosol-generating procedure is being performed
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(e.g. intubation, extubation, cardiopulmonary resuscitation), additional airborne PPE with an
N95 respirator is recommended. Use of telemedicine in place of in-person office visits is a
strategy to minimize physical exposure. Further details have been discussed elsewhere (5,104).
The following considerations specific to the care of patients with thrombotic disease may
be useful. Over-the phone and telemedicine approaches should be considered for all non-urgent
appointments. For necessary in-person visits, visitor restrictions and staggering of appointments
are important considerations (125). For patients with COVID-19 who require urgent procedures,
such as interventions for ACS, high-risk PE, or critical limb ischemia, the fewest number of staff
necessary should be involved. For patients without known infection, healthcare workers should
screen patients for COVID-19 exposures or infectivity, consider appropriate PPE during the
procedure, and apply disinfection techniques post-procedure, as outlined previously (126). In
patients who require, emergent cardiac catheterization with unknown COVID-19 status, airborne
PPE with an N95 respirator and/or Powered Air Purifying Respirator is recommended (127,128).
Considerations for health systems.
Active involvement of health systems with respect to the care of patients with thrombotic
disease are critical to achieving good outcomes for both COVID-19-infected and uninfected
patients. If feasible, resources should be allocated to enable at-home or drive-through INR
checks. Further, system-based considerations should be made to monitor and make necessary
adjustments to algorithms for management of suspected STEMI or severe PE requiring PERT
teams. If procedures are deemed necessary for COVID-19 infected patients, specific protocols
should be put into place regarding PPE use and room disinfection.
Role of Professional Societies
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Professional societies, along with other partners, have an important role in knowledge
generation and dissemination for various aspects of COVID-19 (5,84,104), as well as leading by
example. Illustrative examples include the responsible and wise decisions by the ACC to cancel
the 2020 Annual Scientific Sessions, the SCAI to cancel the 2020 Annual Scientific Sessions,
and the ISTH to cancel the XXVIII Congress of the ISTH to promote social distancing and to
avoid further spread of the disease. Enabling meetings to continue virtually, as with the recent
ACC scientific sessions (in this case at no charge) further promotes knowledge dissemination
and sense of community, allowing a semblance or normality in challenging times. Many
professional societies, including the ACC, the American Heart Association (AHA), American
Society of Hematology, ESC, the ISTH, and others, are compiling COVID-related resources in
dedicated websites. Professional societies can further foster collaborative knowledge generation
by supporting multicenter multinational original research studies to address the pressing clinical
or laboratory questions (Figure 4).
Public Health Considerations Related to Care for Thrombotic Disease
The WHO and government agencies have recognized the critical importance of public
health interventions at the societal level (including social distancing and self-isolation) to
decrease transmission rates and alleviate the burden on health systems (129). In the most affected
areas, governments have enacted mandatory home quarantine for all non-essential personnel
(130-132). There are several important issues to consider as these interventions relate to
thrombotic disease.
First, given the recommendations to stay at home, with decreased daily activity and
sedentary lifestyles, patients may be at increased risk for VTE (133-137). Clinicians should be
aware of this (especially in older adults and higher-risk patients) and provide education on the
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importance of home activities to mitigate this risk (138). Second, as daily routines are disrupted,
dietary changes (especially in daily intake of green vegetables, which are the major source of
vitamin K in the Western diet) may affect patients who receive VKAs. As quarantine measures
become more severe, changes in diet and vitamin K intake may impact INR values. Providers
and patients should be aware of these risks, and patients should be advised to maintain stable diet
to the best of their ability. Third, the COVID-19 pandemic has produced damaging economic
effects (139), with United Nations estimating that COVID-19 is likely to cost the world economy
more than $2 trillion in 2020. These losses may adversely affect patients’ treatment for
thrombotic diseases. Socioeconomic disadvantage has been linked to higher rates of VTE and
adverse outcomes (140,141). As the economic effects of COVID-19 continue to evolve, these
communities may come under new and significant stress.
Future Directions and Conclusions
More data and higher-quality data are required to learn how COVID-19 and thrombotic
disease interact. Such data, ideally derived from prospective, multicenter, multinational studies,
could help to elucidate the similarities and distinctions in disease presentation and outcomes of
patients with COVID-19 and preexisting and incident thromboembolic disease, and help to
identify management strategies to optimize outcomes in these patients. Currently, one large
international registry of patients with venous thromboembolism (the Registro Informatizado
Enfermedad TromboEmbólica [RIETE]) (142) is incorporating data elements for COVID-19,
and a dedicated adjudicated prospective registry to study COVID-19 and other cardiovascular
outcomes is being initiated (CORONA-VTE, BWH Thrombosis Research Group; PI: G. Piazza).
A multicenter multinational ACS registry is has begun and a new AHA registry for
cardiovascular care and outcomes of these patients. Special attention should also be given to
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patients with pre-existing thromboembolic disease who have limited access to care in the face of
the COVID-19 pandemic, which has hindered transportation and limited the resources of the
healthcare system.
Funding agencies, professional societies, and organizations with active patient
participation will all play an important role when it comes to future research in this area. Funding
agencies, including the National Institutes of Health (which has already responded swiftly) (143)
should continue to pay specific attention to this pandemic. Coordination and cooperation are
necessary to quickly address research priorities including those related to thrombotic disease
(Table 5). Organizations such as the Patient-Centered Outcomes Research Institute (PCORI) and
the North American Thrombosis Forum (NATF) can ensure the voices and concerns of patients
are at the forefront of research questions. Professional societies, including the AHA, ESC, ISTH,
IUA, and others should promote knowledge generation and dissemination and advocacy in this
challenging climate.
The current manuscript has provided an interim summary and guidance for
considerations related to thrombotic disease and antithrombotic therapy during the COVID-19
pandemic. Such guidance should supplement, rather than supplant, clinical decision-making.
Nuances of conversations between patients and practitioners should be considered for
appropriate patient-centered decisions.
In conclusion, thrombotic disease may be precedent factors or incident complications in
patients with COVID-19. Important considerations for the preventive and therapeutic use of
antithrombotic agents should be kept in mind to mitigate the thrombotic and hemorrhagic events
in these high-risk patients. Funding agencies, professional societies, patients, clinicians, and

28

investigators should work collaboratively to effectively and efficiently address numerous critical
areas of knowledge gap.
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Bullet Points
•

Coronavirus disease 2019 (COVID-19) may predispose patients to arterial and venous

thrombosis.
•

Initial series suggest the common occurrence of venous thromboembolic disease in

patients with severe COVID-19. The optimal preventive strategy warrants further investigation.
•

Drug-drug interactions between antiplatelet agents and anticoagulants with

investigational COVID-19 therapies should be considered.
•

The available technology should be used optimally to care for patients without COVID-

19 who have thrombotic disease during the pandemic.
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Figure Legends
Figure 1. Variability in resources and testing strategies, and in contracting COVID-19 after
exposure to SARS-CoV-2. Such variability explains the dissimilar population rates of the
infection, and the distinct case fatality rates, across various regions and countries. Inflammatory
response, increased age, and bed-ridden status –which are more frequently observed in severe
COVID-19– may contribute to thrombosis and adverse outcomes. Coronavirus Disease 2019
(COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), VTE indicates
venous thromboembolism.
Figure 2. Risk stratification of acute coronary syndromes and venous thromboembolism
with COVID-19. Proposed algorithm to risk stratify patients based on severity of ACS, VTE,
and COVID-19 presentations. *High-risk ACS refers to patients with hemodynamic instability,
left ventricular dysfunction or focal wall motion abnormality, or worsening or refractory
symptoms. High-risk VTE refers to patients with pulmonary embolism who are
hemodynamically unstable, have evidence of right ventricular dysfunction or dilatation, or with
worsening or refractory symptoms. †High-risk COVID-19 refers to patients with high suspicion
for or confirmed COVID-19, including individuals with high viral load, symptomatic with
coughing/sneezing or other respiratory symptoms and at risk for requiring intubation and
aerosolizing viral particles. ‡Hemodynamic support includes intra-aortic balloon pump,
percutaneous ventricular assist device, and extracorporeal membrane oxygenation.
Hemodynamic monitoring refers to Swan-Ganz catheter for invasive hemodynamic assessment.
For potential drug-drug interactions, please refer to Tables 4 and 5. ACS indicates acute
coronary syndrome; GDMT, guideline-directed medical therapy; TTE, transthoracic
echocardiogram; VTE, venous thromboembolism.
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Figure 3. Considerations for Switching Vitamin-K Antagonists (VKAs) Due to Limitations
with Access to Care or Healthcare Resources During COVID-19 Pandemic. If switching the
anticoagulant agent is planned, care should be taken to be sure that the patient is able to afford
and receive the alternative therapy. Contraindications to DOACs include mechanical heart
valves, valvular AF, pregnancy or breastfeeding, APLS, and co-administration of medications
including strong CYP3A and P-glycoprotein inhibitors (-azole medications, HIV protease
inhibitors [dependent on DOAC, may just require dose reduction], CYP3A4 inducers (antiepileptics), St. John’s Wort, rifampin, etc. Patient education about stable dietary habits while
receiving VKA is also important. If DOACs area not available or approved by insurance,
LMWHs could be used in select cases. Abbreviations: AF: atrial fibrillation, APLS: antiphospholipid syndrome, DOAC: direct oral anticoagulant, INR: international normalized ratio,
LMWH: low-molecular weight heparin, VKA: vitamin-K antagonist.
Figure 4. Considerations for Thrombotic Disease for Patients, Healthcare Providers, and
Health Systems and Professional Societies During the COVID-19 Pandemic. The approach
to safe evaluation and management of thrombotic disease in patients with COVID-19 has several
levels of involvement. Hospitalized patients with existing VTE should continue on
anticoagulation with consideration of drug-drug interactions, especially with antiviral
medications (Table 2). Hospitalized patients with reduced mobility should be started on VTE
prophylaxis. Patients who are discharged or not hospitalized should continue recommended
anticoagulation therapy. Telemedicine and drive-through or home INR checks can reduce the
risk of exposure of both patients and healthcare providers to COVID-19 while assuring proper
management of anticoagulation. In appropriate cases, consider switching VKAs to DOACs to
diminish the need for frequent INR checks (see Figure 4). Healthcare workers should continue
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existing precautions including use of PPE and minimizing individual contact with COVID-19
patients. If emergent procedures for thrombotic disease (e.g. cardiac catheterization, pulmonary
thrombectomy) are needed, procedure rooms should be disinfected and the use of negative
pressure operating rooms should be implemented as available. Expedited funding for
observational and randomized control trials in management of thrombotic disease is encouraged.
aPTT: activated partial thromboplastin time, DOAC: direct oral anticoagulant, INR: international
normalized ratio, PT: prothrombin time, PPE: personal protective equipment, VKA: vitamin-K
antagonist, VTE: venous thromboembolism.
Central Illustration. Postulated Mechanisms of Coagulopathy and Pathogenesis of
Thrombosis in COVID-19. A) Sars-COV-2 infection activates an inflammatory response,
leading to release of inflammatory mediators. Endothelial and hemostatic activation ensues, with
decreased levels of TFPI and increased tissue factor. The inflammatory response to severe
infection is marked by lymphopenia, and thrombocytopenia. Liver injury may lead to decreased
coagulation and antithrombin formation. B) COVID-19 may be associated with hemostatic
derangement and elevated troponin. C) Increased thromboembolic state results in venous
thromboembolism, myocardial infarction, or in case of further hemostatic derangement;
disseminated intravascular coagulation. COPD: chronic obstructive pulmonary disease; CRP: creactive protein; FDP: fibrin degradation product; HF: heart failure; TFPI: tissue factor pathway
inhibitor; IL: interleukin; LDH: lactate dehydrogenase; PT: prothrombin time.
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Table 1. Select Summary of Thrombotic and Thromboembolic Events During Viral Outbreaks
Proposed Mechanisms
Event Type
Epidemiological data
Severe Acute Respiratory Syndrome (SARS)
Venous
•
Inflammatory cytokine release
•
Retrospective analysis of 46 critically ill patients with SARS showed 11 DVT and 7 PE events.(145)
Thromboembolism •
•
Critical illness
Case series of 8 SARS positive ICU patients. Autopsy identified PE in 4, and DVT in 3 individuals.(144)
Arterial
•
Therapeutic risk factors.(144)
•
In a prospective series of 75 patients, 2 patients died of acute myocardial infarction (within 3-week period).(146)
Thrombotic
•
Case report of an NSTEMI patient who received PCI but subsequently developed STEMI several hours later,
Events
concerning for immune-mediated plaque instability.(147)
Other
•
In a case series of 206 patients with SARS, 5 developed large artery ischemic stroke with DIC present in 2/5.(148)
•
In a retrospective analysis of 157 patients with SARS, isolated, subclinical elevations in aPTT were noted in 96
patients and DIC developed in 4 patients.(149)
Middle East Respiratory Syndrome (MERS-CoV)
Other
•
Nonspecific mechanism; potentially
•
In a series of 161 cases of MERS (confirmed and probable), at least 2 were reported to have a consumptive
coagulopathy.(152)
similar to SARS. Models suggest elevated
inflammatory cytokine levels.(150)
•
Transgenic murine models show evidence
of microvascular thrombosis.(151)
Influenza
Venous
•
Possible de novo pulmonary emboli in
•
Retrospective study of 119 patients showed 4 VTE events in patients receiving prophylactic anticoagulation.(154)
Thromboembolism •
certain cases.(153)
Case series describes 7 PEs in patients with influenza pneumonia. In 6/7 there was no evidence of DVT.(153)
•
Acute inflammation and decreased
•
A multicenter, observational, case-control study (n=1454) suggests lower VTE rates are associated with influenza
mobility in hospitalized patients.(154)
vaccination (odds ratio: 0.74; 95% CI: 0.57-0.97).(156)
•
Possible thrombosis due to rupture of pre•
This is a representative but not comprehensive list of associated studies.
existing high risk plaques.(99)
Arterial
•
A self-controlled study of 364 patients hospitalized with acute myocardial infarction found an increased incidence
•
Platelet aggregation over inflamed
Thrombotic
ratio (IR=6.05, 95% confidence interval: 3.86 to 9.50) for myocardial infarction during periods after influenza
atherosclerotic plaques noted in animal
Events
compared with controls.(157) Similar evidence exists in prior studies.(158,159)
models.(155)
•
A retrospective cohort study of 119 patients reports 3 arterial thrombotic events, two of which had STEMI (154).
•
This is a representative but not comprehensive list of associated studies.
Other
•
DIC has been described with influenza infection in a number of case reports and small case series (160-162).
COVID-19
Venous
•
Mechanistic understanding continues to
•
In a preprint retrospective study, 10/25 patients who underwent computed tomography pulmonary angiography had
Thromboembolism
evolve.
acute PE (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3548771)
•
Factors may include inflammatory
•
Two-case series of acute pulmonary embolism were described in patients hospitalized with COVID-19.(83)
cytokine release and critical
•
In a study from 3 hospitals from the Netherlands, 31% of 184 critically-ill patients with COVID-19 had VTE.
illness/therapeutic risk factors.
Arterial
•
Evidence regarding ACS with concurrent COVID-19 infection is limited to anecdotal reports. A pre-print single•
SARS-CoV-2 binds cells expressing
Thrombotic
center retrospective study reported 11 cases of acute ischemic stroke among 221 patients with COVID-19
angiotensin converting enzyme 2 (163) and Events
(https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3550025)
this may mediate further mechanisms of
•
Data are continuing to emerge regarding the risk of thrombotic events associated with COVID-19 infection, and an
injury.(164)
international registry for ACS is planned. Please see text for more detail.
Other
Retrospective analysis of 183 patients found non-survivors had significantly higher D-dimer and PT values, compared with
survivors. Further, 15/21 (71.4%) of non-survivors met criteria for DIC, versus 1/162 (0.6%) of survivors.(7)
Systematic review of literature published prior to February 24, 2020 suggests elevations in PT and D-dimer levels were
associated with poor prognosis in patients with COVID-19.(165)
ACS = acute coronary syndrome; aPTT = activated partial thromboplastin time; COVID-19 = coronavirus disease of 2019; DIC = disseminated intravascular coagulation; DVT = deep vein
thrombosis; ICU= intensive care unit; MERS = Middle East Respiratory Syndrome; NSTEMI = non-ST elevation myocardial infarction; PCI = percutaneous coronary intervention; PE = pulmonary
embolism; PT = prothrombin time; SARS = severe acute respiratory syndrome; STEMI = ST-elevation myocardial infarction; VTE = venous thromboembolism.
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Table 2. Association Between Coagulation Abnormalities or Markers of Thrombosis and Hemostasis and Clinical Outcomes in Patients with COVID-19
Han 2020
(N=94)(24)
Platelet count
Setting of Comparison
Platelet Count

D-dimer (mg/L)
Setting of Comparison
D-dimer (mg/L)

Prothrombin time (s)
Setting of Comparison
Prothrombin time (s)

Troponin (hs-TnI)
Setting of Comparison
Troponin (hs-TnI)

Huang 2020
(N=41)(1)

Yang 2020
(N=52)(26)

Zhou et al
(N=191)(20)

ICU vs. nonICU
196 (165263) vs. 149
(131-263)

Dead vs.
alive
191 (74) vs.
164 (63)

Dead vs.
alive
166 (107229) vs. 220
(168-271)

Severe vs.
non-severe
19.1 vs. 2.1

ICU vs. nonICU
2.4 (0.614.4) vs. 0.5
(0.3-0.8)

Severe vs.
non-severe
12.7 vs. 12.2

ICU vs. nonICU
12.2 (11.213.4) vs.
10.7 (9.812.1)
ICU vs. nonICU
3.3(3.0163.0) vs.
3.5 (0.7-5.4)

Dead vs.
alive
12.9 (2.9)
vs. 10.9
(2.7)

Gao 2020
(N=43)(27)

Wang 2020
(N=138)(16)

Wu 2020
(N=201)(19)

ICU vs. nonICU
142 (110202) vs. 165
(125-188)

Dead vs.
alive
162 (111231) vs. 204
(137-263)

Tang 2020
(N=183)(7)

Severe vs.
non-severe
0.5 (0.3-0.9)
vs. 0.2 (0.20.3)

ICU vs. nonICU
0.4 (0.213.2) vs. 0.2
(0.1-0.3)

Dead vs.
alive
4.0 (1.011.0) vs. 0.5
(0.3-1.2)

Dead vs.
alive
2.1 (0.8-5.3)
vs. 0.6 (0.41.3)

Dead vs.
alive
12.1 (11.213.7) vs.
11.4 (10.412.6)

Severe vs.
non-severe
11.3 (1.4)
vs. 12.0
(1.2)

ICU vs. nonICU
13.2 (12.314.5) vs.
12.9 (12.313.4)

Dead vs.
alive
11.6 (11.112.5) vs.
11.8 (11.012.5)

Dead vs.
alive
15.5 (14.416.3) vs.
13.6 (13.014.0)

ICU vs. nonICU
11.0 (5.626.4) vs. 5.1
(2.1-9.8)

Lippi 2020
(N=553)(23)

Lippi 2020
(N=341)(36)

Dead vs.
alive
-48 (-57 - 39)*^

Dead vs.
alive
5.2 (1.521.1) vs. 0.6
(0.3-1.0)

Dead vs.
alive
22.2 (5.683.1) vs. 3.0
(1.1-5.5)

Lippi 2020
(N=1779)(2
2)

Severe vs.
non-severe
3.0 (2.53.5)*

Severe vs.
non-severe
25.6 (6.844.5)*
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Table 3. Potential Drug Interactions Between Antiplatelet Agents* and Investigational Therapies for COVID-19
P2Y12 Platelet Receptor Inhibitors
Investigational COVID-19
Therapies
Lopinavir/
Ritonavir

Mechanism of Action of COVID-19 Therapy
Lopinavir is a protease inhibitor; Ritonavir inhibits CYP3A4 metabolism
increasing lopinavir levels

Remdesivir

Nucleotide-analog inhibitor of RNA-dependent RNA polymerases

Clopidogrel 1,2

Prasugrel 2

Ticagrelor 3,4

CYP 3A4 Inhibition (minor pathway):
Reduction in clopidogrel active metabolite.
Do not co-administer or if available utilize
P2Y12 platelet function assays for
monitoring.† With limited clinical data,
prasugrel may be considered as alternative,
if no contraindications
Reported inducer of CYP3A4 (minor
pathway): No dose adjustment
recommended.

CYP3A4 Inhibition: Decreased
active metabolite but maintained
platelet inhibition. Can administer
with caution.

CYP3A4 Inhibition:
Increased effects of ticagrelor.
Do not co-administer or if
available utilize P2Y12
monitoring or consider dosereduced ticagrelor*

CYP3A4 Inhibition:
Recommend decreasing dose
to maximum of 50 mg BID.

Reported inducer of
Reported inducer of
CYP3A4 (major pathway):
CYP3A4 (major pathway):
No dose adjustment
No dose adjustment
recommended.
recommended.
Tocilizumab
Inhibits IL-6 receptor: may potentially mitigate cytokine release syndrome
Reported increase in expression of 2C19
Reported increase in expression of
Reported increase in
Reported increase in
symptoms in severely ill patients
(major pathway) and 1A2, 2B6, and 3A4
3A4 (major pathway) and 2C9 and
expression of 3A4 (major
expression of 3A4 (major
(minor pathways: No dose adjustment
2C19 (minor pathway): No dose
pathway): No dose
pathway): No dose
recommended.
adjustment recommended.
adjustment recommended.
adjustment recommended.
Sarilumab
Binds specifically to both soluble and membrane-bound IL-6Rs (sIL-6Rα and
Reported increase in expression of 3A4
Reported increase in expression of
Reported increase in
Reported increase in
mIL-6Rα) and has been shown to inhibit IL-6-mediated signaling: may
(minor pathways: No dose adjustment
3A4 (major pathway): No dose
expression of
expression of 3A4 (major
potentially mitigate cytokine release syndrome symptoms in severely ill
recommended.
adjustment recommended.
pathway): No dose
CYP3A4(major pathway):
patients
No dose adjustment
adjustment recommended.
recommended.
Other drugs being studied to treat COVID-19 include azithromycin, bevacizumab, chloroquine/hydroxychloroquine, eculizumab, fingolimod, interferon, losartan, methylprednisolone, pirfenidone, and ribavirin. Drug-drug interactions between these medications and
antiplatelet agents have yet to be identified. *Cangrelor, aspirin, dipyridamole, and glycoprotein IIb/IIIa inhibitors (eptifibatide, tirofiban, abciximab) are not known to interact with investigational therapies for COVID-19.
†Monitoring of P2Y12 levels can be assessed through the VerifyNow assay, or others. Evaluation of effect of protease inhibitors on P2Y12 inhibitors has not been extensively studied. Dose reduction recommendations for P2Y12 inhibitors or P2Y12 platelet function
assay monitoring is not commonly practiced.
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Reported inducer of CYP3A4
(major pathway): No dose
adjustment recommended.

Phosphodiesterase III
Inhibitor
Cilostazol

Table 4. Potential Drug Interactions Between Anticoagulants* and Investigational Therapies for COVID-19
Oral Anticoagulants
Investigational COVID-19
Therapies

Vitamin K antagonists

Dabigatran

CYP2C9 induction:
May decrease plasma concentration. Adjust
dose based on INR

P-gp inhibition:
May increase plasma
concentration. No dose
adjustment recommended

Tocilizumab

-

-

Interferon‡

Unknown mechanism:
Decreased dose may be needed
Mechanism not well known:
Possibly decreased absorption of warfarin in
the presence of ribavirin.(166)
Increased dose may be needed

Lopinavir/Ritonavir

Ribavirin

Methylprednisolone

Unknown mechanism:
Decreased dose may be needed

Betrixaban

Edoxaban

P-gp and ABCB1 inhibition:
Decrease dose to 80 mg once
followed by 40 mg once daily

P-gp inhibition:
Do not co-administer

Reported increase in expression of
3A4 (major pathway): No dose
adjustment recommended

-

-

Reported increase in expression of 3A4
(major pathway): No dose adjustment
recommended

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

CYP3A4 and P-gp inhibition:
Administer at 50% of dose
(do not administer if initial dose is 2.5
mg twice daily)†

Reported increase in expression of
CYP3A4 (major pathway): No dose
adjustment recommended

Sarilumab§

Azithromycin

Apixaban

Unknown mechanism: Decreased dose may
be needed

P-gp inhibition:
May increase plasma
concentration. No dose
adjustment recommended

Rivaroxaban

CYP3A4 and P-gp inhibition:
Do not co-administer

Reported increase in expression of
CYP3A4 (major pathway): No dose
adjustment recommended
P-gp inhibition:
Decrease dose to 80 mg once
followed by 40 mg daily

P-gp inhibition:
VTE: Limit dose to 30 mg
daily.
Non-valvular AF: No dose
recommendation

Hydroxychloroquine and
Chloroquine
Other drugs being studied to treat COVID-19 include bevacizumab, chloroquine/hydroxychloroquine, eculizumab, fingolimod, losartan, and pirfenidone. Drug-drug interactions between these medications and oral anticoagulants have yet to be identified. Bevacizumab
has been reported to cause deep vein thrombosis (9%), arterial thrombosis (5%) and pulmonary embolism (1%). It is also reported to cause thrombocytopenia (58%).*Parenteral anticoagulants (including unfractionated or low-molecular weight heparins, bivalirudin,
argatroban, and fondaparinux) are non CYP metabolized and don’t interact with any of the investigational agents #Reported with interferon alpha. †These recommendations are based on the U.S. package insert. The Canadian package insert considers the combination of
these agents to be contraindicated. ‡Interferon has been reported to cause pulmonary embolism (<5%), thrombosis (<5%), decreased platelet count (1-15% with Alfa-2b formulation), and ischemic stroke (<5%). §Sarilumab has been reported to cause decreased platelet
count, with decreases to less than 100,000 mm3 in 1% an 0.7% of patients on 200 mg and 150 mg doses, respectively. CYP: Cytochrome P system. |
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Table 5. Areas Requiring Further Investigation
Patients with Mild COVID-19 (outpatient)
To determine the optimal method for risk assessment for outpatients with mild COVID-19 who are
at risk of VTE
To determine the incidence acute coronary syndromes in population-based studies
Patients with Moderate or severe COVID-19 without DIC (hospitalized)
To determine the incidence and predictors of VTE among patients with COVID-19 who present with
respiratory insufficiency and/or hemodynamic instability. These include lower extremity DVTs,
central-line associated DVT in upper or lower extremities, and also PE.
To develop an appropriate algorithm for the diagnosis of incident VTE in patients with COVID-19.

To determine the optimal total duration of prophylactic anticoagulation
To determine the optimal dose of prophylactic anticoagulation in specific populations (e.g. those
with obesity or advanced kidney disease)
To determine if LMWH constitutes the preferred method of pharmacological prophylaxis
To determine the optimal method for risk stratification and VTE prophylaxis after hospital discharge

To determine if routine use of higher doses of anticoagulants (i.e. higher than prophylactic doses as
described in the international guidelines), confer net benefit
To determine the incidence and predictors of type I acute myocardial infarction in patients with
COVID-19, and to compare their process measures and outcomes with non-infected patients.
To determine the potential role of agents including danaparoid, fondaparinux, and sulodexide in
select patients with moderate/severe COVID-19.
Patients with Moderate or Severe COVID-19 and suspected or confirmed DIC (hospitalized)
To determine if routine use of pharmacological VTE prophylaxis or low or standard dose
anticoagulation with UFH or LMWH is warranted (if no overt bleeding)
To determine if additional clinical characteristics and variables in the setting of DIC (e.g.
lymphopenia) should be considered to help risk-stratify and assess prognosis
To determine utility of other interventions including antithrombin concentrates.
Patients without COVID-19 but with co-morbidities, and homebound during the pandemic
To determine the optimal method of screening and risk stratification for consideration of VTE
prophylaxis

Comment
The options include the Caprini model, the IMPROVE model, and the Padua model,
and others for assessment of the risk of VTE. These should be weighed against the
risk of bleeding.

Prospective multicenter cohort (observational) data needed, these protocols should
not interfere and could run in parallel with interventional trials which are planned or
already underway.
D-dimer is elevated in many inpatients with COVID-19, although negative value
may still be helpful. In some cases of COVID-19 with worsening hypoxemia, CTPA
may be considered instead of non-contrast CT (which only assesses the pulmonary
parenchyma. Unresolved issues include diagnostic tests for critically-ill patients,
including those in prone position, with limited options for CTPA or ultrasonography.
Ultrasound screening in select patients may need to be studied.
Weight-adjusted prophylactic dosing for patients with obesity, or dosing based on
creatinine clearance in patients with kidney disease require further investigation.
The options include the Caprini model, the IMPROVE model, and the Padua model,
and others for assessment of the risk of VTE. These should be weighed against the
risk of bleeding.
An important question would be whether monitoring anti-Xa activity would be
preferable over aPTT.

A relevant question is whether prophylactic, or other, dose anticoagulation should be
given to patients with DIC who do not have bleeding, even without immobility

The options include the Caprini model, the IMPROVE model, and the Padua model,
and others for assessment of the risk of VTE. These should be weighed against the
risk of bleeding.
To conduct population-level studies to determine the trends in incidence and outcomes of thrombotic Although telemedicine is reasonable to control the COVID-19 pandemic, potential
disease in the period of reduced office visits
adverse consequences on non-communicable disease, including thrombotic disease
deserve investigation.
aPTT: activated partial thromboplastin time, COVID-19: Coronavirus disease 2019; CTPA: computed tomography pulmonary angiography; LMWH: low-molecular weight heparin; PE: pulmonary
embolism; VTE: Venous thromboembolism
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Table 6. Summary of Consensus Recommendation on Antithrombotic Therapy During the COVID-19 Pandemic
Patients with Mild COVID-19 (outpatient)
For outpatients with mild COVID-19, increased mobility should be encouraged. Although indiscriminate use of pharmacological VTE prophylaxis should not be pursued, assessment for the risk of VTE
and of bleeding is reasonable. Pharmacologic prophylaxis could be considered after risk assessment on an individual case basis for patients who have elevated risk VTE, without high bleeding risk.*
There is no known risk of developing severe COVD-19 due to taking antithrombotic agents (i.e. antiplatelet agents or anticoagulants). If patients have been taking antithrombotic agents for prior known
thrombotic disease, they should continue their antithrombotic agents as recommended.
For outpatients on vitamin K antagonists who do not have recent stable INRs, and are unable to undergo home or drive-through INR testing, it is reasonable to transition the treatment DOACs if there
are no contraindications and no problems with drug availability and affordability. If DOACs are not approved or available, low-molecular weight heparin can be considered as alternative.*
Patients with Moderate or Severe COVID-19 without DIC (hospitalized)
Hospitalized patients with COVID-19 should undergo risk stratification for VTE prophylaxis.
For hospitalized patients with COVID-19 and not in DIC, prophylactic doses of anticoagulation can be administered to prevent VTE.*¥† If pharmacological prophylaxis is contraindicated, it is
reasonable to consider intermittent pneumatic compression.
For hospitalized patients with COVID-19 and not in DIC, there is insufficient data to consider routine therapeutic or intermediate-dose parenteral anticoagulation with UFH or LMWH.*‡
Routine screening for VTE (e.g. bilateral lower extremity ultrasound) for hospitalized patients with COVID-19 with elevated D-Dimer (>1,500 ng/mL) cannot be recommended at this point&
Patients with Moderate or Severe COVID-19 and suspected or confirmed DIC (hospitalized)
For patients with moderate or severe COVID-19 and in DIC but without overt bleeding, prophylactic anticoagulation should be administered.*¥§
For hospitalized patients with COVID-19 with suspected or confirmed DIC, but no overt bleeding, there is insufficient data to consider routine therapeutic or intermediate-dose parenteral
anticoagulation with UFH or LMWH.*β
For patients with moderate or severe COVID-19 on chronic therapeutic anticoagulation, who develop suspected or confirmed DIC without overt bleeding, it is reasonable to consider the indication for
anticoagulation and weigh with risk of bleeding when making clinical decisions regarding dose adjustments or discontinuation. The majority of authors of this manuscript recommended reducing the
intensity of anticoagulation in this clinical circumstance, unless the risk of thrombosis considered to be exceedingly high. ||
For patients with moderate or severe COVID-19 and an indication for dual antiplatelet therapy (e.g. percutaneous coronary intervention within the past 3 months or recent myocardial infarction) and
with suspected or confirmed DIC without overt bleeding, in the absence of evidence, decisions for antiplatelet therapy need to be individualized. In general, it is reasonable to continue dual antiplatelet
therapy if platelet count >50,000, reduce to single antiplatelet therapy if 25,000<platelet count<50,000; and discontinue if platelets <25,000. However, these guidelines may be revised upward or
downward depending on the individualized relative risk of thrombotic complications vs. bleeding.
For patients who were admitted and are now being discharged for COVID-19, routine screening for VTE risk is reasonable for consideration of pharmacological prophylaxis for up to 45 days postdischarge. Pharmacological prophylaxis should be considered if there is elevated risk for thrombotic events, without high bleeding risk. *#
Ambulation and physical activity should be encouraged.
Patients with COVID-19 presenting with ACS
For presentations concerning for STEMI and COVID-19, clinicians should weigh the risks and severity of STEMI presentation with that of potential COVID-19 severity in the patient, as well as risk of
COVID-19 to the individual clinicians and to the healthcare system at large. Decisions for primary percutaneous coronary intervention or fibrinolytic therapy should be informed by this assessment.*
Patients without COVID-19 who have previously-known thrombotic disease
There is no known risk of developing severe COVD-19 due to taking antithrombotic agents. Patients should continue their antithrombotic agents as recommended.
To minimize risks associated with healthcare worker and patient in-person interactions, follow-up with e-visits and telemedicine is preferable in most cases.
Patients without COVID-19 who develop new thrombotic disease
To minimize risks associated with healthcare worker and patient in-person interactions, in-home treatment or early discharge should be prioritized.
To minimize risks associated with healthcare worker and patient in-person interactions, follow-up with e-visits and telemedicine is preferable in most cases.
Patients without COVID-19 but with co-morbid conditions (e.g. prior VTE, active cancer, major cardiopulmonary disease), who are homebound during the pandemic
Recommendations include increased mobility, and risk assessment for the risk of VTE and risk of bleeding is reasonable. Administration of pharmacologic prophylaxis could be considered after risk
assessment on an individual case basis for patients who have elevated risk for thrombotic events, without high bleeding risk.
*Indicates recommendations as reached by consensus of at least 66% of authors determined via Delphi method. ¥Although high-quality data are lacking, some panel members (55%) considered it reasonable to use
intermittent pneumatic compression in patients with severe COVID-19, in addition to pharmacological prophylaxis. Specific areas of concern included limited data on use in the prone position as well as potential
high incidence of preexisting asymptomatic DVT. †If VTE prophylaxis is considered, enoxaparin 40mg daily or similar LMWH regimen (e.g. dalteparin 5000U daily) can be administered. Subcutaneous heparin
(5000U twice to three times per day) can be considered for patients with renal dysfunction (i.e. creatinine clearance <30 mL/min). ‡While the majority of the writing group did make this recommendation, 31.6% of
the group were in favor of intermediate-dose anticoagulation [e.g. enoxaparin 1mg/kg/day, or enoxaparin 40mg BID, or UFH with target aPTT of 50-70] and 5.2% considered therapeutic anticoagulation. &The
majority of the investigators recommended against routine VTE screening (68%); however, the remaining members of the group (32%) recommended to consider such testing. §The majority of the investigators
recommended prophylactic anticoagulation (54%). A minority of investigators (29.7%) voted for intermediate-dose parenteral anticoagulation in this setting, and 16.2% considered therapeutic anticoagulation. ||While
the majority of investigators voted to reduce the intensity of anticoagulation if the indication were not acute (62%), this survey question did not meet prespecified cut-off of 66%. #The majority of the writing group
recommended prophylaxis with DOACs (51%) and minority (24%) recommended LMWH, if available and appropriate. ACS: acute coronary syndrome; DOAC: direct oral anticoagulant, LMWH, low-molecular
weight heparin; STEMI, ST-segment elevation myocardial infarction; UFH, unfractionated heparin; VTE, venous thromboembolism.
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